TABLE 3.
Treatment effect on urinary excretion profile of abacavir, 2269W93, and 361W94, as percentage of administered dose
| Drug and parameter | Abacavir treatment (n = 25) | Abacavir-ethanol treatment (n = 24) | Median difference in % excreteda |
|---|---|---|---|
| Abacavirb | |||
| GLSM (95% CI)c | 2.54 (2.15, 2.94) | 3.91 (3.37, 4.44) | |
| Median (range) | 2.51 (0.98, 5.60) | 3.80 (1.69, 7.24) | 1.38* (0.73, 1.91) |
| 2269W93b | |||
| GLSM (95% CI) | 26.88 (24.39, 29.36) | 10.14 (8.34, 11.95) | |
| Median (range) | 26.78 (16.04, 40.55) | 9.00 (5.11, 22.56) | −17* (−17.70, −13.04) |
| 361W94b | |||
| GLSM (95% CI) | 24.54 (22.50, 26.57) | 35.72 (31.00, 40.43) | |
| Median (range) | 23.51 (17.01, 36.40) | 36.60 (7.34, 63.39) | 11.0* (7.28, 14.11) |
| Totalb | |||
| GLSM (95% CI) | 53.96 (50.10, 57.82) | 49.77 (44.25, 55.29) | |
| Median (range) | 51.08 (37.44, 71.58) | 53.81 (18.80, 71.35) | −4.0 (−8.11, 1.58) |
a
Data for 2269W93 and 361W94 are expressed as abacavir equivalents. ∗, P ≤ 0.05.
b
Treatment difference represents median percentage change from treatment 1 (abacavir) to treatment 2 (abacavir plus ethanol) with 90% CI.
c
Geometric least squares means (GLSMs) with 95% CIs are presented as percentages of administered doses excreted within the 12-h postdosing collection interval.